Skip to main content

Table 3 Prognostic factors for overall survival in the eribulin arm

From: Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review

Variables

n

HR

95 % CI

P value

Lung metastasis

27

0.90

0.42–1.95

0.79

Liver metastasis

36

1.25

0.56–2.78

0.59

Bone metastasis

43

1.42

0.58–3.50

0.44

CNS metastasis

9

1.36

0.44–4.17

0.59

Other metastasis

47

0.46

0.20–1.02

0.06

Anthracycline-based regimen for EBC

21

0.51

0.15–1.73

0.28

Anthracycline-based regimen for MBC

24

0.36

0.11–0.83

0.02*

Taxane-based regimen for EBC

13

0.48

0.08–2.77

0.41

Taxane-based regimen for MBC

41

0.66

0.22–1.96

0.45

Eribulin as first-/second-line for MBC

31

0.90

0.37–2.20

0.82

Taxane-based regimen prior to eribulin

28

1.41

0.63–3.14

0.40

Duration of eribulin treatment >median (125 days)

33

0.45

0.21–0.94

0.03*

  1. CI confidence interval, CNS central nervous system, EBC early breast cancer, HR hazard ratio, MBC metastatic breast cancer